Drug General Information |
Drug ID |
D0Q5DI
|
Former ID |
DIB020523
|
Drug Name |
nexturastat A
|
Synonyms |
S7473
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
|
Formula |
C19H23N3O3
|
InChI |
InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)
|
InChIKey |
JZWXMCPARMXZQV-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
163338793, 163347740, 163501714, 177218166, 184024322, 184024343, 184525742, 184525763, 184525784, 187051806, 210275560, 210281208, 223366959, 226088094, 240242956, 251962694, 252160951, 252448869, 252451435, 252472671
|
Target and Pathway |
Target(s) |
Histone deacetylase 1 |
Target Info |
Inhibitor |
[1]
|
Histone deacetylase 6 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Cell cycle
|
Notch signaling pathway
|
Thyroid hormone signaling pathway
|
Huntington's disease
|
Amphetamine addiction
|
Alcoholism
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Viral carcinogenesis
|
MicroRNAs in cancer
|
Chronic myeloid leukemiahsa05034:Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Wnt signaling pathway
|
p53 pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Notch signaling pathway
|
E2F transcription factor network
|
Presenilin action in Notch and Wnt signaling
|
Signaling events mediated by HDAC Class I
|
Regulation of Telomerase
|
Glucocorticoid receptor regulatory network
|
Sumoylation by RanBP2 regulates transcriptional repression
|
Regulation of Androgen receptor activity
|
IL3-mediated signaling events
|
Validated nuclear estrogen receptor alpha network
|
Retinoic acid receptors-mediated signaling
|
Hedgehog signaling events mediated by Gli proteins
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Validated targets of C-MYC transcriptional repression
|
Regulation of retinoblastoma protein
|
Notch-mediated HES/HEY networkhdac_classii_pathway:Signaling events mediated by HDAC Class II
|
Reactome
|
G0 and Early G1
|
p75NTR negatively regulates cell cycle via SC1
|
Formation of the beta-catenin:TCF transactivating complex
|
NOTCH1 Intracellular Domain Regulates Transcription
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
HDACs deacetylate histones
|
Deactivation of the beta-catenin transactivating complex
|
NoRC negatively regulates rRNA expression
|
RNA Polymerase I Transcription Initiation
|
Factors involved in megakaryocyte development and platelet productionR-HSA-2122947:NOTCH1 Intracellular Domain Regulates Transcription
|
Assembly of the primary cilium
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Notch Signaling Pathway
|
TGF beta Signaling Pathway
|
IL-6 signaling pathway
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
Notch Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Neural Crest Differentiation
|
TWEAK Signaling Pathway
|
Integrated Breast Cancer Pathway
|
Signalling by NGF
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
Androgen receptor signaling pathwayWP2858:Ectoderm Differentiation
|
References |
REF 1 | Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9. |